Moreover, CD44 silencing experiments in prostate cancer were performed to demonstrate that the loss of this receptor activity is associated with tumor recurrence and progression [89]; also, the majority of prostate cancer metastases lack the expression of this molecule [90]. The gene discussed is CD44; the disease is prostate carcinoma.